Amorcyte, LLC, a NeoStem, Inc. company (AMEX: NBS) announced the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction. The study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of infarct-related artery infusion of AMR-001, an autologous ...
25
JAN
JAN
0
Share
